Orelabrutinib

• Recruiting NCT NCT04961515

  Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

  Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 19 participants Est. completion 2026-12-31 1 site Stand-alone
  Other conditions: Primary Central Nervous System Hodgkin Lymphoma
  View official trial listing →
• Recruiting NCT NCT04989621

  Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

  Not yet reported Sun Yat-sen University 32 participants Est. completion 2028-08 3 sites Stand-alone
  Other conditions: Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma
  View official trial listing →
• Recruiting NCT NCT05209620

  Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

  Not yet reported Henan Cancer Hospital 30 participants Est. completion 2026-12-21 1 site Stand-alone
  Other conditions: Central Nervous System Lymphoma
  View official trial listing →
• Recruiting NCT NCT05600660

  Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma

  Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 28 participants Est. completion 2027-12-31 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Recruiting NCT NCT05728658

  The Study of ICP-248 in Patients With Mature B-cell Malignancies

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 191 participants Est. completion 2026-10-30 22 sites Stand-alone
  Other conditions: Hematological Malignancies
  View official trial listing →
• Recruiting NCT NCT05933967

  A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

  Not yet reported Shandong Cancer Hospital and Institute 31 participants Est. completion 2026-12-30 2 sites Stand-alone
  Other conditions: The First Affiliated Hospital of Nanchang University
  View official trial listing →
• Recruiting NCT NCT06082102

  Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 324 participants Est. completion 2030-02-25 19 sites Stand-alone
  Other conditions: Relapsed/Refractory Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06134284

  Clinical Study of OR for Second-line Treatment of Refractory MZL

  Not yet reported Lixia Sheng 39 participants Est. completion 2029-12-31 3 sites Stand-alone
  Other conditions: OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06228963

  Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

  Not yet reported Fudan University 160 participants Est. completion 2028-01 1 site Stand-alone
  Other conditions: MALT Lymphoma of Stomach, Helicobacter Pylori Infection
  View official trial listing →
• Recruiting NCT NCT06363994

  A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

  Not yet reported InnoCare Pharma Inc. 476 participants Est. completion 2032-06-25 39 sites
  Other conditions: Mantle Cell Lymphoma
  View official trial listing →
• Recruiting NCT NCT06378138

  ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

  Not yet reported, Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 226 participants Est. completion 2031-07-25 53 sites Stand-alone
  Other conditions: Hematologic Malignancies
  View official trial listing →
• Recruiting NCT NCT06454968

  Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

  Not yet reported Peking Union Medical College Hospital 45 participants Est. completion 2028-06-01 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06478472

  Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy

  Not yet reported The First Affiliated Hospital of Xiamen University 36 participants Est. completion 2027-06-23 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06496308

  Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment

  Not yet reported Ruijin Hospital 78 participants Est. completion 2027-07-10 1 site Stand-alone
  Other conditions: Mantle Cell Lymphoma (MCL)
  View official trial listing →
• Recruiting NCT NCT06503276

  The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy

  Not yet reported Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 50 participants Est. completion 2028-10-31 1 site Stand-alone
  Other conditions: Extranodal Marginal Zone B-cell Lymphoma
  View official trial listing →
• Recruiting NCT NCT06504940

  Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

  Not yet reported First Affiliated Hospital of Zhejiang University 69 participants Est. completion 2029-07-08 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06513234

  Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

  Not yet reported Institute of Hematology & Blood Diseases Hospital, China 45 participants Est. completion 2029-06-21 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06566807

  Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

  Not yet reported Huai'an First People's Hospital 51 participants Est. completion 2028-08-10 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT06647940

  Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

  Not yet reported Sun Yat-sen University 39 participants Est. completion 2027-03-01 11 sites Stand-alone
  Other conditions: Diffuse Large B Cell Lymphoma (DLBCL)
  View official trial listing →
• Recruiting NCT NCT06700798

  Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

  Not yet reported Fei Li 90 participants Est. completion 2027-12-04 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Recruiting NCT NCT06701357

  CR-CHOP+X in Previously Untreated DEL

  Not yet reported Ruijin Hospital 49 participants Est. completion 2028-12-01 1 site Stand-alone
  Other conditions: DLBCL
  View official trial listing →
• Recruiting NCT NCT06793189

  MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

  Not yet reported Ruijin Hospital 145 participants Est. completion 2028-12-31 3 sites Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Recruiting NCT NCT06958705

  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 79 participants Est. completion 2028-02-01 1 site Stand-alone
  Other conditions: Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
  View official trial listing →
• Recruiting NCT NCT06985472

  Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

  Not yet reported Li Zhiming 33 participants Est. completion 2027-12-31 2 sites Stand-alone
  Other conditions: Initial MZL, Untreated MZL, BTKi, CD20
  View official trial listing →
• Recruiting NCT NCT07022223

  Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma

  Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 51 participants Est. completion 2029-09-11 18 sites Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Recruiting NCT NCT07067463

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  Not yet reported Zenas BioPharma (USA), LLC 705 participants Est. completion 2030-07 68 sites Stand-alone
  Other conditions: Multiple Sclerosis (MS) Primary Progressive
  View official trial listing →
• Recruiting NCT NCT07072208

  Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL

  Not yet reported The First Affiliated Hospital of Soochow University 43 participants Est. completion 2027-05-01 1 site Stand-alone
  Other conditions: Diffuse Large B-Cell Lymphoma
  View official trial listing →
• Recruiting NCT NCT07078500

  Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma

  Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 48 participants Est. completion 2028-12-31 1 site Stand-alone
  Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
  View official trial listing →
• Recruiting NCT NCT07185373

  Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

  Not yet reported, Not yet reported Huashan Hospital 215 participants Est. completion 2029-07-30 15 sites Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Recruiting NCT NCT07191431

  A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）

  Not yet reported Ruijin Hospital 25 participants Est. completion 2029-09-02 1 site Stand-alone
  Other conditions: Lymphoma Cns
  View official trial listing →
• Recruiting NCT NCT07199296

  Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

  Not yet reported Ruijin Hospital 45 participants Est. completion 2028-07-01 1 site Stand-alone
  Other conditions: Mantle Cell Lymphoma (MCL)
  View official trial listing →
• Recruiting NCT NCT07208981

  Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 169 participants Est. completion 2031-06-01 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Recruiting NCT NCT07257510

  Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

  Not yet reported Peking University Third Hospital 34 participants Est. completion 2028-08-01 1 site Stand-alone
  Other conditions: Mantle Cell Lymphoma (MCL), POZ
  View official trial listing →
• Recruiting NCT NCT07272499

  Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

  Not yet reported Ruijin Hospital 25 participants Est. completion 2028-09-10 1 site Stand-alone
  Other conditions: Mantle Cell Lymphoma (MCL)
  View official trial listing →
• Recruiting NCT NCT07299019

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  Not yet reported Zenas BioPharma (USA), LLC 990 participants Est. completion 2030-07 52 sites Stand-alone
  Other conditions: Secondary Progressive Multiple Sclerosis
  View official trial listing →
• Recruiting NCT NCT07350850

  A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL

  Not yet reported Tongji Hospital 77 participants Est. completion 2029-06-30 4 sites
  Other conditions: PCNSL, Primary Central Nervous System Lymphoma
  View official trial listing →
• Recruiting NCT NCT07355699

  Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

  Not yet reported Beijing Tongren Hospital 88 participants Est. completion 2028-12-31 3 sites Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Recruiting NCT NCT07372365

  Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.

  Not yet reported The First Affiliated Hospital of Soochow University 23 participants Est. completion 2030-10-01 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma (MZL)
  View official trial listing →
• Recruiting NCT NCT07377578

  A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

  Not yet reported Guangzhou Lupeng Pharmaceutical Company LTD. 394 participants Est. completion 2033-01-30 2 sites
  Other conditions: Mantle Cell Lymphoma
  View official trial listing →
• Recruiting NCT NCT07410520

  PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2029-12-31 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
  View official trial listing →
• Recruiting NCT NCT07441993

  Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

  Not yet reported Institute of Hematology & Blood Diseases Hospital, China 30 participants Est. completion 2028-12 14 sites Stand-alone
  Other conditions: Marginal Zone Lymphoma
  View official trial listing →
• Recruiting NCT NCT07448324

  Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 50 participants Est. completion 2030-01-01 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Recruiting NCT NCT07453368

  Orelabrutinib in the Treatment of Relapsed/Refractory AIHA

  Not yet reported Peking Union Medical College Hospital 50 participants Est. completion 2028-03-01 1 site Stand-alone
  Other conditions: Autoimmune Hemolytic Anemia (AIHA)
  View official trial listing →
• Recruiting NCT NCT07499271

  Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

  Not yet reported The First Affiliated Hospital of Soochow University 35 participants Est. completion 2027-12-31 1 site Stand-alone
  Other conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
  View official trial listing →
• Recruiting NCT NCT07554898

  Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma

  Not yet reported Zhejiang Cancer Hospital 60 participants Est. completion 2029-01-01 2 sites Stand-alone
  Other conditions: MALT Lymphoma
  View official trial listing →
• Recruiting NCT NCT07559331

  High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

  Not yet reported Shandong University 86 participants Est. completion 2028-12-31 1 site Stand-alone
  Other conditions: Primary Immune Thrombocytopenia (ITP)
  View official trial listing →
• Recruiting NCT NCT07680933

  Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

  Not yet reported The Affiliated Hospital of Xuzhou Medical University 30 participants Est. completion 2028-12-31 1 site Stand-alone
  Other conditions: DLBCL - Diffuse Large B Cell Lymphoma
  View official trial listing →
• Recruiting NCT NCT07719556

  Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 39 participants Est. completion 2029-07-01 2 sites Stand-alone
  Other conditions: Mantle Cell Lymphoma (MCL)
  View official trial listing →
• Recruiting NCT NCT07778212

  Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

  Not yet reported The First Affiliated Hospital of Xiamen University 30 participants Est. completion 2028-12-31 2 sites Stand-alone
  Other conditions: DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
  View official trial listing →
• Active, not recruiting NCT NCT04014205

  A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

  Not yet reported, Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 81 participants Est. completion 2026-06-30 36 sites Stand-alone
  Other conditions: Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
  View official trial listing →
• Status unknown NCT NCT04304040

  A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

  Not yet reported, Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 43 participants Est. completion 2025-12-30 10 sites Stand-alone
  Other conditions: B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
  View official trial listing →
• Completed NCT NCT04305197

  A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

  Not yet reported, Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 60 participants Est. completion 2022-04-28 11 sites
  Other conditions: Systemic Lupus Erythematosus
  View official trial listing →
• Status unknown NCT NCT04711148

  A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 160 participants Est. completion 2026-03-01 42 sites Stand-alone
  Other conditions: Relapsing Remitting Multiple Sclerosis
  View official trial listing →
• Status unknown NCT NCT04831658

  A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

  Not yet reported, Not yet reported Mingzhi Zhang 40 participants Est. completion 2024-09-15 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Status unknown NCT NCT04899427

  Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

  Not yet reported Peking Union Medical College Hospital 32 participants Est. completion 2023-10-24 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Status unknown NCT NCT05014100

  Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

  Not yet reported Puyang Oilfield General Hospital 55 participants Est. completion 2023-09-30 Stand-alone
  Other conditions: B-cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05020288

  A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

  Not yet reported Shandong University 40 participants Est. completion 2024-06-01 Stand-alone
  Other conditions: Immune Thrombocytopenia, Bruton's Tyrosine Kinase
  View official trial listing →
• Status unknown NCT NCT05021770

  Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

  Not yet reported, Not yet reported Huiqiang Huang 29 participants Est. completion 2024-06 1 site Stand-alone
  Other conditions: Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma
  View official trial listing →
• Completed NCT NCT05036577

  A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL

  Not yet reported Huashan Hospital 13 participants Est. completion 2025-03-30 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Completed NCT NCT05051891

  A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 3 participants Est. completion 2025-06-30 22 sites Stand-alone
  Other conditions: Treatment-naїve Mantle Cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05076097

  A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

  Not yet reported Tianjin Medical University Cancer Institute and Hospital 29 participants Est. completion 2023-10-15 1 site Stand-alone
  Other conditions: Mantle Cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05097443

  Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

  Not yet reported Shandong Provincial Hospital 130 participants Est. completion 2024-12-31 1 site Stand-alone
  Other conditions: High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, B-cell NonHodgkin Lymphoma
  View official trial listing →
• Status unknown NCT NCT05124028

  A Study of Orelabrutinib in Patients With ITP

  Not yet reported, Not yet reported Peking University People's Hospital 10 participants Est. completion 2022-06-01 1 site Stand-alone
  Other conditions: Immune Thrombocytopenia
  View official trial listing →
• Status unknown NCT NCT05232149

  A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 30 participants Est. completion 2024-12-30 9 sites Stand-alone
  Other conditions: Primary Immune Thrombocytopenia
  View official trial listing →
• Status unknown NCT NCT05234684

  A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 150 participants Est. completion 2025-12-30 44 sites Stand-alone
  Other conditions: Diffuse Large B Cell Lymphoma (DLBCL)
  View official trial listing →
• Status unknown NCT NCT05284175

  A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

  Not yet reported Peking Union Medical College Hospital 23 participants Est. completion 2023-08 1 site Stand-alone
  Other conditions: Neuromyelitis Optica Spectrum Disorder
  View official trial listing →
• Completed NCT NCT05316857

  DDI Study of Orelabrutinib

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 36 participants Est. completion 2022-06-13 1 site
  Other conditions: Healthy Person
  View official trial listing →
• Status unknown NCT NCT05322733

  Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 25 participants Est. completion 2025-11-05 1 site Stand-alone
  Other conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  View official trial listing →
• Status unknown NCT NCT05334238

  Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

  Not yet reported Ruijin Hospital 174 participants Est. completion 2025-05-30 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Status unknown NCT NCT05351346

  Genotype-guided Treatment in DLBCL

  Not yet reported Ruijin Hospital 1100 participants Est. completion 2026-06-01 1 site Stand-alone
  Other conditions: Diffuse Large B Cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05381506

  Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma

  Not yet reported Sun Yat-sen University 77 participants Est. completion 2025-12 8 sites Stand-alone
  Other conditions: DLBCL
  View official trial listing →
• Status unknown NCT NCT05390749

  Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

  Not yet reported Peking Union Medical College Hospital 50 participants Est. completion 2026-04-01 3 sites Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Status unknown NCT NCT05491044

  A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

  Not yet reported Peking University People's Hospital 30 participants Est. completion 2024-08-30 2 sites Stand-alone
  Other conditions: CLL/SLL
  View official trial listing →
• Status unknown NCT NCT05495828

  Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

  Peking University People's Hospital 30 participants Est. completion 2025-03-10 1 site
  Other conditions: B-cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05498259

  Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

  Not yet reported The First Affiliated Hospital of Soochow University 46 participants Est. completion 2025-01-01 1 site Stand-alone
  Other conditions: Diffuse Large B-Cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05549284

  Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)

  Not yet reported Affiliated Hospital to Academy of Military Medical Sciences 36 participants Est. completion 2026-05-30 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Status unknown NCT NCT05660720

  Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 48 participants Est. completion 2023-08-31 1 site Stand-alone
  Other conditions: Healthy Subject
  View official trial listing →
• Status unknown NCT NCT05684653

  Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 34 participants Est. completion 2023-12-30 4 sites Stand-alone
  Other conditions: Hepatic Impairment
  View official trial listing →
• Status unknown NCT NCT05688696

  Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 186 participants Est. completion 2026-05-30 41 sites Stand-alone
  Other conditions: Systemic Lupus Erythematosus, SLE
  View official trial listing →
• Status unknown NCT NCT05784987

  R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 60 participants Est. completion 2025-01-01 Stand-alone
  Other conditions: Diffuse Large B-cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT05809180

  Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

  Not yet reported The First Affiliated Hospital of Soochow University 35 participants Est. completion 2026-07-03 1 site Stand-alone
  Other conditions: Diffuse Large B Cell Lymphoma
  View official trial listing →
• Not yet recruiting NCT NCT05918276

  Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

  Not yet reported Nanfang Hospital, Southern Medical University 24 participants Est. completion 2026-12-30 2 sites Stand-alone
  Other conditions: CLL/SLL
  View official trial listing →
• Status unknown NCT NCT05920668

  Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

  Wang Xin 20 participants Est. completion 2025-07-01 1 site
  Other conditions: CLL/SLL
  View official trial listing →
• Status unknown NCT NCT05926427

  Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

  Not yet reported Ruijin Hospital 25 participants Est. completion 2026-04-30 1 site Stand-alone
  Other conditions: CNS Lymphoma
  View official trial listing →
• Status unknown NCT NCT05975164

  the Real World Study of Orelabrutinib in the Treatment of CLL/SLL

  Shandong University 50 participants Est. completion 2024-07-10
  Other conditions: CLL/SLL
  View official trial listing →
• Completed NCT NCT05978739

  Evaluating Different Doses of Orelabrutinib in MCL

  Not yet reported InnoCare Pharma Inc. 40 participants Est. completion 2024-12-10 20 sites Stand-alone
  Other conditions: Mantle Cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT06004856

  Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 195 participants Est. completion 2026-04-30 45 sites Stand-alone
  Other conditions: Chronic Primary Immune Thrombocytopenia (ITP)
  View official trial listing →
• Status unknown NCT NCT06015464

  An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

  The First Affiliated Hospital with Nanjing Medical University 81 participants Est. completion 2025-07-30 1 site
  Other conditions: Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
  View official trial listing →
• Completed NCT NCT06115824

  New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen

  Huashan Hospital 136 participants Est. completion 2024-07-30 1 site
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Status unknown NCT NCT06290817

  Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

  Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 62 participants Est. completion 2026-03-20 6 sites Stand-alone
  Other conditions: Diffuse Large B-cell Lymphoma
  View official trial listing →
• Completed NCT NCT06454266

  First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

  Not yet reported Ningbo No. 1 Hospital 22 participants Est. completion 2024-07-25 1 site Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma
  View official trial listing →
• Not yet recruiting NCT NCT06476899

  A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

  Not yet reported Fei Li 60 participants Est. completion 2026-12-26 Stand-alone
  Other conditions: CLL/SLL
  View official trial listing →
• Status unknown NCT NCT06508684

  Current Status of BTKi Treatment for CLL/SLL in China

  The First Affiliated Hospital with Nanjing Medical University 1000 participants Est. completion 2025-07-12 1 site
  Other conditions: CLL/SLL
  View official trial listing →
• Not yet recruiting NCT NCT06516978

  A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

  Not yet reported The First Affiliated Hospital with Nanjing Medical University 528 participants Est. completion 2029-04-01 Stand-alone
  Other conditions: Diffuse Large B Cell Lymphoma
  View official trial listing →
• Status unknown NCT NCT06530511

  Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

  Not yet reported Affiliated Hospital of Nantong University 30 participants Est. completion 2026-08-01 2 sites Stand-alone
  Other conditions: Diffuse Large B Cell Lymphoma
  View official trial listing →
• Active, not recruiting NCT NCT06583837

  Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

  Not yet reported Fudan University 50 participants Est. completion 2027-09 1 site Stand-alone
  Other conditions: Lymphoma, B-Cell, Marginal Zone
  View official trial listing →
• Not yet recruiting NCT NCT06656221

  A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

  Not yet reported Ruijin Hospital 29 participants Est. completion 2028-05-01 Stand-alone
  Other conditions: Mantle Cell Lymphoma
  View official trial listing →
• Not yet recruiting NCT NCT06901999

  Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients

  Not yet reported Ruijin Hospital 23 participants Est. completion 2028-11 Stand-alone
  Other conditions: CNS Lymphoma
  View official trial listing →
• Not yet recruiting NCT NCT07008053

  BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma

  Not yet reported Tianjin Medical University Cancer Institute and Hospital 37 participants Est. completion 2028-11 6 sites Stand-alone
  Other conditions: Marginal Zone Lymphomas
  View official trial listing →
• Not yet recruiting NCT NCT07198464

  Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

  Not yet reported Zhengzhou University 30 participants Est. completion 2029-10-01 Stand-alone
  Other conditions: Primary Central Nervous System Lymphoma (PCNSL)
  View official trial listing →
• Not yet recruiting NCT NCT07206264

  Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment

  Not yet reported Tianjin Medical University Cancer Institute and Hospital 45 participants Est. completion 2028-12 5 sites Stand-alone
  Other conditions: Mantle Cell Lymphoma
  View official trial listing →
• Active, not recruiting NCT NCT07247383

  Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

  Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 39 participants Est. completion 2028-12-31 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Not yet recruiting NCT NCT07400250

  Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy

  Not yet reported Peking Union Medical College Hospital 28 participants Est. completion 2028-10-01 1 site Stand-alone
  Other conditions: Primary Immune Thrombocytopenia (ITP)
  View official trial listing →
• Active, not recruiting NCT NCT07480863

  Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

  Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 65 participants Est. completion 2029-10-02 1 site Stand-alone
  Other conditions: Marginal Zone Lymphoma(MZL)
  View official trial listing →
• Not yet recruiting NCT NCT07492407

  CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma

  Henan Cancer Hospital 131 participants Est. completion 2028-02
  Other conditions: MZL
  View official trial listing →
• Not yet recruiting NCT NCT07574073

  CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia

  Not yet reported Qi deng 30 participants Est. completion 2028-05-31 Stand-alone
  Other conditions: Anti-CD20 Monoclonal Antibody, BTK Inhibitors, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA)
  View official trial listing →
• Not yet recruiting NCT NCT07585747

  A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

  Not yet reported Institute of Hematology & Blood Diseases Hospital, China 27 participants Est. completion 2030-12-31 5 sites Stand-alone
  Other conditions: Follicular Lymphoma
  View official trial listing →
• Not yet recruiting NCT NCT07677813

  Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

  Not yet reported Ou Bai, MD/PHD 66 participants Est. completion 2031-12-31 1 site Stand-alone
  Other conditions: DLBCL - Diffuse Large B Cell Lymphoma
  View official trial listing →
• Not yet recruiting NCT NCT07705308

  A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

  Not yet reported Ruijin Hospital 140 participants Est. completion 2031-05-01 3 sites Stand-alone
  Obstructive sleep apnea
  View official trial listing →
• Not yet recruiting NCT NCT07719855

  A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

  Not yet reported Ruijin Hospital 652 participants Est. completion 2033-12 1 site Stand-alone
  Other conditions: Follicular Lymphoma ( FL)
  View official trial listing →
• Not yet recruiting NCT NCT07784101

  A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

  Not yet reported Beijing InnoCare Pharma Tech Co., Ltd. 280 participants Est. completion 2033-12 24 sites Stand-alone
  Other conditions: Relapsed or Refractory Mantle Cell Lymphoma (MCL)
  View official trial listing →
• Not yet recruiting NCT NCT07875972

  Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)

  Not yet reported Liu Qing 12 participants Est. completion 2028-10 Stand-alone
  Other conditions: Amyotrophic Lateral Sclerosis (ALS)
  View official trial listing →

Not yet reported.

Not yet reported.

• ClinicalTrials.gov — NCT07875972

No related coverage yet.